IP Library Granted Patent US 7,527,933
Granted Patent B2
US 7,527,933 · App. 10/537,002 · Granted May 5, 2009

Genetic products differentially expressed in tumors and the use thereof

Assignee: Ganymed Pharmaceuticals AG
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,527,933
App. No.
10/537,002
Granted
May 5, 2009
Kind
B2
Abstract

The invention relates to the identification of genetic products expressed in association with tumors and to coding nucleic acids for the expressed products. An embodiment of the invention also relates to the therapy and diagnosis of disease in which the genetic products are aberrantly expressed in association with tumors, proteins, polypeptides and peptides which are expressed in association with tumors, and to the nucleic acids coding for the polypeptides, peptides and proteins.

Claims (10)

1. A method of diagnosing lung, pancreatic, or esophageal cancer, comprising detecting expression of a tumor-associated antigen in a biological sample, wherein the tumor-associated antigen is selected from the group consisting of:

(i) the polypeptide of SEQ ID NO: 16; and

(ii) the polypeptide encoded by the nucleic acid of SEQ ID NO: 7,

wherein detection of the tumor-associated antigen in a biological sample isolated from a patient in an amount greater than an amount of the tumor-associated antigen in a normal biological sample indicates the presence of lung, pancreatic, or esophageal cancer.

2. The method of claim 1 , in which the detection comprises:

(i) contacting the biological sample with an antibody which binds specifically to the tumor-associated antigen; and

(ii) detecting a complex formed between the antibody and the tumor-associated antigen.

3. The method of claim 2 , wherein the antibody is labeled with a detectable marker.

4. The method of claim 3 , wherein the detectable marker is a radioactive marker or an enzymatic marker.

5. The method of claim 1 , wherein the biological sample comprises body fluid or body tissue.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 1, 2005
From: SAHIN, UGUR; TURECI, OZLEM; KOSLOWSKI, MICHAEL
To: GANYMED PHARMACEUTICALS AG
Reel/Frame 017082/0105 →
Priority Claims (1)
DE 102 54 601 · Nov 22, 2002 · national
Continuity (1)
Related Publication 20060035852A1 · Feb 16, 2006